clinical trial · NCT04833582
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc·phase1·completed·n = 31
OsteosarcomaAzenosertibGemcitabine
brief summary
This is a phase 1/2 study of azenosertib (ZN-c3) in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.
started
Aug 1, 2021
primary completion
Aug 30, 2023
completion
Mar 30, 2024
last updated
Apr 3, 2026
detailed description
This is a phase 1/2 dose escalation and dose expansion study, evaluating the clinical activity and safety, pharmacodynamics, and pharmacokinetics of azenosertib (ZN-c3) in combination with gemcitabine in relapsed or refractory osteosarcoma.
official title
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination With Gemcitabine in Adult and Pediatric Subjects With Relapsed or Refractory Osteosarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol